Schedule 13G ownership disclosure
BIODEXA PHARMACEUTICALS PLC ADR
ADSs · CUSIP: 59564R880
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- SABBY MANAGEMENT, LLC
Shares: 217,600.00 · Class: 9.9%
- Hal Mintz
Shares: 217,600.00 · Class: 9.9%
- Sabby Volatility Warrant Master Fund, Ltd.
Shares: 217,600.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001535610-26-000008
- Form type
- SCHEDULE 13G
- Filer
- Biodexa Pharmaceuticals Plc
- CIK
- CIK 1643918
- Filed
- Jan 20, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership